Clinical Trial Update: 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating the radiopharmaceutical 177Lu-DOTA-EB-TATE in adults with metastatic, radioactive iodine non-responsive Hurthle cell (oncocytic) th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hurthle Cell Thyroid Carcinoma
• Thyroid Cancer

Drugs mentioned

• 177Lu-DOTA-EB-TATE

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Thyroid Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING